Press Releases :: Aurinia Pharmaceuticals Inc. (AUPH)

December 12, 2019 • 9:26 am EST

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

December 9, 2019 • 9:00 pm EST

Aurinia Prices US$166.7 Million Public Offering of Common Shares

December 9, 2019 • 6:01 am EST

Aurinia Announces Public Offering of Common Shares

December 4, 2019 • 4:05 pm EST

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

December 3, 2019 • 6:30 am EST

Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

November 14, 2019 • 4:02 pm EST

Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

November 13, 2019 • 4:05 pm EST

Aurinia Announces Updates to the Board of Directors

November 7, 2019 • 6:30 am EST

Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil

November 6, 2019 • 4:05 pm EST

Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019

October 31, 2019 • 6:30 am EDT

Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome

Select a page:

rss_feed News RSS

©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23